Literature DB >> 3932786

Pituitary adenomas associated with hyperprolactinemia: a clinical and immunohistochemical study of 97 patients operated on transsphenoidally.

R V Randall, B W Scheithauer, E R Laws, C F Abbound, M J Ebersold, P C Kao.   

Abstract

Immunohistochemical studies were performed on the tumors of 97 of 100 patients who had undergone an operation for a presumed prolactin-secreting pituitary adenoma; no tissue was available for study in the other 3 patients. Appropriate immunohistochemical studies were done to identify the presence of growth hormone, prolactin, adrenocorticotropic hormone, luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone within the adenoma cells. The presence of a prolactin-producing pituitary adenoma was confirmed in 91 patients, 3 of whom had an adenoma that consisted of cells that contained prolactin and growth hormone. One other patient, not counted among the 91 with prolactinoma, had lactotrope and thyrotrope hyperplasia. Among the five patients whose adenoma did not contain prolactin cells, four had a null cell adenoma and one had a tumor consisting of follicle-stimulating hormone and luteinizing hormone immunoreactive cells. On the basis of preoperative serum prolactin values in these patients, we concluded that moderately increased values (30 to 200 ng/ml) of serum prolactin are not a reliable guide for determining whether a prolactin-producing pituitary adenoma is present, whereas levels exceeding 200 ng/ml are usually associated with a prolactin-secreting tumor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932786     DOI: 10.1016/s0025-6196(12)60417-0

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  9 in total

Review 1.  Hyperprolactinemia: neuroendocrine and diagnostic aspects.

Authors:  F Camanni; E Ciccarelli; E Ghigo; E E Müller
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

2.  Medical and surgical management of microprolactinoma.

Authors:  William T Couldwell; Martin H Weiss
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 3.  Human pituitary adenomas. Recent advances in morphological studies.

Authors:  G Giannattasio; M Bassetti
Journal:  J Endocrinol Invest       Date:  1990-05       Impact factor: 4.256

Review 4.  Medical management of hypopituitarism in patients with pituitary adenomas.

Authors:  Baha M Arafah
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 5.  Stereotactic radiosurgery for pituitary adenomas: a review of the literature.

Authors:  Edward R Laws; Jason P Sheehan; Jonas M Sheehan; Jay Jagnathan; John A Jane; Rod Oskouian
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

6.  Estrogen receptors in prolactinomas: a clinico-pathological study.

Authors:  G J Kaptain; N E Simmons; T D Alden; M B Lopes; M L Vance; E R Laws
Journal:  Pituitary       Date:  1999       Impact factor: 4.107

7.  Serum prolactin concentration at presentation of non-functioning pituitary macroadenomas.

Authors:  L A Behan; E P O'Sullivan; N Glynn; C Woods; R K Crowley; T K Tun; D Smith; C J Thompson; A Agha
Journal:  J Endocrinol Invest       Date:  2013-02-04       Impact factor: 4.256

8.  The pituitary stalk effect: is it a passing phenomenon?

Authors:  Marvin Bergsneider; Leili Mirsadraei; William H Yong; Noriko Salamon; Michael Linetsky; Marilene B Wang; David L McArthur; Anthony P Heaney
Journal:  J Neurooncol       Date:  2014-02-19       Impact factor: 4.130

9.  Descriptive Epidemiology and Survival Analysis of Prolactinomas and Cushing's Disease in Korea.

Authors:  Jin Sun Park; Soo Jin Yun; Jung Kuk Lee; So Young Park; Sang Ouk Chin
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.